Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb-Mar;21(1):6-14.

Update of the drug resistance mutations in HIV-1: March 2013

Victoria A Johnson  1 , Vincent Calvez, Huldrych F Gunthard, Roger Paredes, Deenan Pillay, Robert W Shafer, Annemarie M Wensing, Douglas D Richman
Affiliations

Update of the drug resistance mutations in HIV-1: March 2013

Victoria A Johnson et al. Top Antivir Med. 2013 Feb-Mar.

Erratum in

  • Top Antivir Med. 2013 Apr-May;21(2):46
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial Disclosures: The authors (listed alphabetically) disclose the following affiliations with commercial organizations that may have interests related to the content of this article (previous 12 months): Dr Calvez has served on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc, Roche, and ViiV Healthcare. Dr Günthard has served as a medical advisor and/or consultant for Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen-Cilag, Pfizer Inc, Tibotec Therapeutics, and ViiV Healthcare, with all compensation going to his institution, University Hospital of Zurich. He has received unrestricted research and educational grants to his institution from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmith-Kline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer Inc, and Tibotec Therapeutics. Dr Johnson has received research support from Abbott Molecular, Roche Molecular Diagnostics, and Siemens Healthcare Diagnostics Inc. Dr Paredes has served as a consultant or medical advisor for Roche Diagnostics and ViiV Healthcare, and has received research grants awarded to IrsiCaixa and Lluita Contra la SIDA Foundations from Merck Sharp & Dohme Corp and ViiV Healthcare. Dr Pillay received laboratory support for University College London from ViiV Healthcare. Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, Chimerix, Gen-Probe Inc, Gilead Sciences, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, and Tobira Therapeutics. He has held stock options for Chimerix. Dr Shafer has served as a consultant or medical advisor for Celera and Siemens Healthcare and has received grants from F. Hoffmann-La Roche Ltd, and Gilead Sciences, Inc. Dr Wensing has served as a consultant or medical advisor for Gilead Sciences, Inc, and ViiV Healthcare; has received grants from Merck & Co, Inc, and ViiV Healthcare; and has received travel, accommodations, or meeting expenses from Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, and Virology Education.

References

    1. Johnson VA, Calvez V, Günthard HF, et al. 2011 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4)156-164. - PMC - PubMed
    1. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448. - PubMed
    1. DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438. - PubMed
    1. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resis-tant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718-727. - PMC - PubMed
    1. Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Antimicrob Agents Chemother. 2012;56(8):4522-4524 - PMC - PubMed

Publication types

LinkOut - more resources